Human CD2 / CD20 Antibody from EXALPHA BIOLOGICALS, INC.
Search, find, compare suppliers for anti-Human CD2 / CD20 antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Human CD2 / CD20 |
| Clone | monoclonal |
| Host Species | Mouse |
| Reactive Species | human |
| Isotype | IgG2a (F)/IgG1 (PE) |
| Format | FITC/PE conjugate, 2-color reagent |
| Size | 100 Tests |
| Concentration | Titered for flow cytometry |
| Applications | Flow Cytometry |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Mouse anti Human CD2 FITC - CD20 PE |
| Immunogen | CD2=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with t lymphocytes activated by mixed lymphocyte culture. CD20=Derived from the hybridization of mouse Sp2/0 myeloma cells with spleen cells from BALB/c mice immunized with the LB lymphoblastoid cell line. |
| Other Names | CD2 FITC - CD20 PE |
| Gene, Accession # | UniProt: P06729, P11836 |
| Catalog # | 220 |
| Price | $374 |
| Order / More Info | Human CD2 / CD20 Antibody from EXALPHA BIOLOGICALS, INC. |
| Product Specific References | 1.An Improved Rosetting Assay for Detection of Human T Lymphocytes. Kaplan M.E., Clark C., J. Immunol. Methods 1974, 5,131 2.Structural and functional characterization of the CD2 immunoadhesion domain. Evidence for inclusion of CD2 in an alpha-beta protein folding class. Recny M.A., Neidhardt E.A., Sayre P.H., Ciardelli T.L., Reinherz E.L., J. Biol. Chem. 1990 May 2;265(15):85419 3. Partial deletions of the cytoplasm domain of CD2 result in a partial defect in signal transduction. Bierer B.E., Bogart R.E., Burakoff S.J., J. Immunol. 1990 Feb. :144(3):785 4. Functional CD2 mutants unable to bind to, or be stimulated by, LFA-3. Wolff H.L., Burakoff S.J., Bierer B.E., J. Immunol. 1990 Feb. 1;144(4):1215-20 5. Association of CD2 and CD45 on human T lymphocytes. Schraven B., Samstag Y., Altevogt P., Meuer S.C., Nature 1990 May ;345(6270):71-4 6. In vivo and in vitro expression of myeloid antigens on B-lineage acute lymphoblastic leukemia cells. Leukemia 1991 Ja;5(1):19-25 Hara J; Kawa-Ha K; Yumura-Yagi K; Kurahashi H; Tawa A; Ishihara S; Inoue M; Murayama N; Okada S. 7. Activation of dense human tonsilar B cells. Induction of c-myc gene expression via two distinct signal transduction pathways. J Immunol 1991 Feb ;146(3):846-53 White MW; McConnell F; Shu GL; Morris DR; Clark EA. 8. Differential effects of low and high concentrations of interleukin 6 on human B cells. Eur J Immunol 1990 No;20(11):2389-93 Levy Y; Fermand JP; Brouet JC. 9. Immunophenotypes in 'classical' B-cell chronic lymphocytic leukemia. Correlation with normal cellular counterpart and clinical findings. Cancer 1990 Oct 1;66(8):1738-42 Baldini L; Cro L; Cortelezzi A; Calori R; Nobili L; Maiolo AT; Polli EE. 10. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood 1990 Oct 1;76(8):1647-56 Small TN; Keever CA; Weiner-Fedus S; Heller G; O'Reilly RJ; Flomenberg N. 11. Phenotypic analysis of a large number of normal human bone marrow sample by flow cytometry. Blut 1990 No;61(5):271-7 Andreoni C; Rigal D; Bonnard M; Bernaud J. 12. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood 1990 Nov ;76(9):1739-47 Terstappen LW; Johnsen S; Segers-Nolten IM; Loken MR. |
EXALPHA BIOLOGICALS, INC.
EXALPHA BIOLOGICALS, INC.
2 Shaker Road, Unit B101
Shirley MA 01464
P: 978-425-1370
info@exalpha.com
https://www.exalpha.com
Profile of EXALPHA BIOLOGICALS, INC.
Return to Antibodies